Build­ing on its reti­nal dis­ease ex­per­tise, Re­gen­eron signs eye-fo­cused gene ther­a­py pact with Ger­man biotech

Re­gen­eron beefed up its gene ther­a­py ca­pa­bil­i­ties Wednes­day, sign­ing a new deal with the Ger­man biotech Vi­Gen­eron.

The sim­i­lar­ly named — but un­re­lat­ed — com­pa­nies an­nounced the col­lab­o­ra­tion ear­ly Wednes­day morn­ing, one which would see Vi­Gen­eron re­ceive undis­closed up­front and mile­stone pay­ments in ex­change for Re­gen­eron get­ting ac­cess to its suite of re­com­bi­nant ade­no-as­so­ci­at­ed virus vec­tors.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN